Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

doi:10.4251/wjgo.v8.i2.173

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10148)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

690

WORD

396

HTML

4222

Figures (1-1)

492

Tables (1-3)

203

Sum=6003

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

409

Download

1032

Sum=1441

Publishing Process of This Article

Item

Count

Browse

1132

Download

1572

Sum=2704

Feb 15, 2016 (publication date) through Oct 4, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Feb 15, 2016; 8(2): 173-185
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.173

Open in New Tab Full Size Figure Download Figure

Figure 1 Novel compounds under investigation and their predominant targets. EGFR: Epidermal growth factor receptor; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet derived growth factor receptor; FGFR: Fibroblast growth factor receptor; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase; mTOR: Mammalian target of rapamycin.

Citation: Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016; 8(2): 173-185
URL: https://www.wjgnet.com/1948-5204/full/v8/i2/173.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i2.173